China’s medical products regulator said on Thursday that it had approved two more Covid-19 vaccines for public use, raising the number of domestically produced vaccines that can be used in China to four, Reuters reports.

The two newly-cleared vaccines are made by CanSino Biologics Inc (CanSinoBIO) and Wuhan Institute of Biological Products, an affiliate of China National Pharmaceutical Group (Sinopharm).

They join a vaccine from Sinovac Biotech approved earlier this month, and another from Sinopharm’s Beijing unit approved last year.

Prior to formal approval for wider public use by the National Medical Products Administration, millions of doses of the two Sinopharm vaccines and Sinovac shot had been administered in China’s vaccination program. The program targets select groups of people facing a higher risk of infection.